Eli Lilly (LLY) says Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at USD 25/month with commercial coverage and USD 149/month with self-pay
Context
Eli Lilly's announcement about Foundayo pricing suggests a strategic move to increase market accessibility for its GLP-1 weight loss treatment. With a competitive price point and commercial coverage, this launch may enhance their revenue potential and provide a positive read-through for the pharmaceuticals sector, particularly in the weight loss market.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ELI LILLY & CO#LLY.US#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#DXY#US EQUITIES